← Back to Clinical Trials
Recruiting NCT07189715

NCT07189715 Optimization of Imagery Rescripting Research Using Generative Artificial Intelligence

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07189715
Status Recruiting
Phase
Sponsor University of Social Sciences and Humanities, Warsaw
Condition Generalized Anxiety
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2025-06-01
Primary Completion 2025-11-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 35 Years
Study Type INTERVENTIONAL
Interventions
Imagery Rescripting Intervention (AI-Generated)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2025-06-01 with a primary completion date of 2025-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This pilot randomized controlled trial will investigate the feasibility and effectiveness of using generative artificial intelligence to create personalized therapeutic scripts for imagery rescripting (ImRs). Eighty participants will listen to autobiographical scenarios based on their own memories of childhood criticism and neutral events. The scenarios will be generated by the Gemini large language model and reviewed by trained experimenters. On Day 1, all participants will be exposed to both critical and neutral scenarios and randomly assigned to either an experimental group receiving an ImRs intervention or a control group receiving no therapeutic modification. Skin conductance and subjective emotional ratings will be collected during the session, with follow-up questionnaires administered one week later. In addition, cognitive-behavioral therapists will evaluate the quality of the generated scripts. The study aims to assess emotional and physiological responses to AI-generated content, compare outcomes between groups, and explore the potential of large language models in scalable psychological interventions.

Eligibility Criteria

Inclusion Criteria: * Age 18-35 * Score ≥ 8 on GAD-7 (Plummer et al., 2016) * Ability to recall at least two childhood memories involving parental criticism Exclusion Criteria: * History of prolonged physical or sexual abuse * Current psychotherapy or psychopharmacology * PTSD diagnosis (DSM-5 screening) * Substance abuse (TAPS tool)

Contact & Investigator

Central Contact

Stanisław Karkosz, MA

✉ skarkosz@swps.edu.pl

📞 +48 570 668 996

Principal Investigator

Stanisław Karkosz, MA

PRINCIPAL INVESTIGATOR

SWPS University

Frequently Asked Questions

Who can join the NCT07189715 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 35 Years, studying Generalized Anxiety. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07189715 currently recruiting?

Yes, NCT07189715 is actively recruiting participants. Contact the research team at skarkosz@swps.edu.pl for enrollment information.

Where is the NCT07189715 trial being conducted?

This trial is being conducted at Poznan, Poland.

Who is sponsoring the NCT07189715 clinical trial?

NCT07189715 is sponsored by University of Social Sciences and Humanities, Warsaw. The principal investigator is Stanisław Karkosz, MA at SWPS University. The trial plans to enroll 80 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology